1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 39, 02/Oct/2025
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Between December 2024 and August 2025, two Italian HIV/STI clinics offered long-acting injectable cabotegravir (CAB-LA) for HIV prevention in 265 individuals, representing the first European real-world implementation. Participants were prioritised based on vulnerabilities compromising oral pre-exposure prophylaxis (PrEP), such as poor adherence, comorbidities and behavioural barriers. Adherence to injections exceeded 95%, tolerability was favourable and only 1.5% discontinued for drug-related reasons. These findings demonstrate the feasibility of CAB-LA in European clinical services and support its use in specific populations.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.39.2500739
2025-10-02
2026-04-14
/content/10.2807/1560-7917.ES.2025.30.39.2500739
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/39/eurosurv-30-39-2.html?itemId=/content/10.2807/1560-7917.ES.2025.30.39.2500739&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC) and WHO Regional Office for Europe. (WHO/Europe). HIV/AIDS surveillance in Europe 2024 – 2023 data. Stockholm and Copenhagen: ECDC and WHO/Europe; 2024. Available from: https://www.ecdc.europa.eu/en/publications-data/hiv-aids-surveillance-europe-2024-2023-data
  2. European AIDS Clinical Society (EACS). EACS Guidelines Version 12.1 – Pre-exposure Prophylaxis (PrEP). 2024. Available from: https://eacs.sanfordguide.com/eacs-part1/art/eacs-pre-exposure-prophylaxis
  3. British Association for Sexual Health and HIV (BASHH), & British HIV Association (BHIVA). (2024). Draft BASHH/BHIVA guidelines on the use of HIV pre-exposure prophylaxis (PrEP) (Version 3.0, 24 September 2024). Available from: https://www.bashh.org/_userfiles/pages/files/draft_bashh_bhiva_prep_guidelines_240924_v30_final.pdf
  4. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595-608.  https://doi.org/10.1056/NEJMoa2101016  PMID: 34379922 
  5. Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-89.  https://doi.org/10.1016/S0140-6736(22)00538-4  PMID: 35378077 
  6. Mazzotta V, Caruso E, Tavelli A, Esvan R, Lanini S, Micheli G, et al. HIV oral pre-exposure prophylaxis effectiveness, adherence, and discontinuation in an Italian multicentric access program: ItaPrEP Study. Open Forum Infect Dis. 2025;12(9):ofaf539.  https://doi.org/10.1093/ofid/ofaf539  PMID: 40980566 
  7. World Health Organization (WHO). Guidelines on long-acting injectable cabotegravir for HIV prevention. Geneva: WHO; 2022. Available from: https://www.who.int/publications/i/item/9789240054097
  8. European Centre for Disease Prevention and Control (ECDC)/WHO Regional Office for Europe (WHO/Europe). HIV/AIDS surveillance in Europe 2024 – 2023 data. Stockholm: ECDC/WHO/Europe; 2024. Available from: https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance-europe-2024-2023-data
  9. Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331-40.  https://doi.org/10.1016/S2352-3018(17)30068-1  PMID: 28546090 
  10. Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15(11):e1002690.  https://doi.org/10.1371/journal.pmed.1002690  PMID: 30408115 
  11. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803-15.  https://doi.org/10.1056/NEJMoa1902824  PMID: 31339677 
  12. Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, et al. , Preexposure Prophylaxis Initiative Study Team. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(4):572-80.  https://doi.org/10.1093/cid/civ324  PMID: 25908682 
  13. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. , iPrEx study team. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820-9.  https://doi.org/10.1016/S1473-3099(14)70847-3  PMID: 25065857 
  14. European Centre for Disease Prevention and Control (ECDC). Pre-exposure prophylaxis for HIV prevention in Europe and Central Asia: Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia – 2023 progress report. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/pre-exposure-prophylaxis-hiv-prevention-europe-and-central-asia-2023
  15. Gandhi RT, Landovitz RJ, Sax PE, Smith DM, Springer SA, Günthard HF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2025;333(7):609-28.  https://doi.org/10.1001/jama.2024.24543  PMID: 39616604 
Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Davide+Moschese&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Moschese Davide</a>, <a href="/search?value1=Rozenn+Esvan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Esvan Rozenn</a>, <a href="/search?value1=Chiara+Fusetti&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fusetti Chiara</a>, <a href="/search?value1=Virginia+Barchi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Barchi Virginia</a>, <a href="/search?value1=Maria+Vittoria+Cossu&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cossu Maria Vittoria</a>, <a href="/search?value1=Alessandro+Giacinta&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Giacinta Alessandro</a>, <a href="/search?value1=Samuel+Lazzarin&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lazzarin Samuel</a>, <a href="/search?value1=Giulia+Terracini&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Terracini Giulia</a>, <a href="/search?value1=Francesco+Caruso&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Caruso Francesco</a>, <a href="/search?value1=Giulia+Micheli&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Micheli Giulia</a>, <a href="/search?value1=Donatella+Maddalena&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Maddalena Donatella</a>, <a href="/search?value1=Giulia+Del+Duca&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Del Duca Giulia</a>, <a href="/search?value1=Francesco+Petri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Petri Francesco</a>, <a href="/search?value1=Gianluca+Frate&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Frate Gianluca</a>, <a href="/search?value1=Maddalena+Matone&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Matone Maddalena</a>, <a href="/search?value1=Damiano+Farinacci&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Farinacci Damiano</a>, <a href="/search?value1=Andrea+Giacomelli&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Giacomelli Andrea</a>, <a href="/search?value1=Paolo+Faccendini&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Faccendini Paolo</a>, <a href="/search?value1=Debora+Visigalli&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Visigalli Debora</a>, <a href="/search?value1=Sara+Passacantilli&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Passacantilli Sara</a>, <a href="/search?value1=Agostino+Riva&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Riva Agostino</a>, <a href="/search?value1=Andrea+Antinori&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Antinori Andrea</a>, <a href="/search?value1=Andrea+Gori&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gori Andrea</a>, <a href="/search?value1=Valentina+Mazzotta&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mazzotta Valentina</a></span>. Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(39):pii=2500739. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.39.2500739" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.39.2500739</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 20 Sept 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 02 Oct 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.39.2500739
/content/10.2807/1560-7917.ES.2025.30.39.2500739
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error